P7 protein resistance mutations identified-represent drug targets for hepatitis c virus
Tuesday, June 28, 2011 - 12:30
in Health & Medicine
Researchers have identified specific resistance mutations for two classes of p7 inhibitor, which may explain their lack of effectiveness in clinical trials combined with current standard of care. Study results support the role of p7 inhibitor combinations as potential components of future HCV-specific therapies.